Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Tang Capital Management, Kevin Tang and affiliated funds report beneficial ownership of 12,229,500 Aurinia Pharmaceuticals common shares, representing 9.2% of the class. This stake is based on 132,970,979 common shares outstanding as of February 25, 2026. The amendment also notes that Kevin Tang was appointed Chief Executive Officer of Aurinia Pharmaceuticals on March 23, 2026.
Aurinia Pharmaceuticals Inc. announced a major management transition, appointing Kevin Tang, currently Chair of the Board, as Chief Executive Officer and principal executive officer effective March 23, 2026. Tang has a long background in life sciences investing and biotech leadership and has elected to receive no salary, bonuses, equity awards or other compensation from Aurinia.
The Board also appointed Ryan Cole as Chief Operating Officer and Michael Hearne as Chief Financial Officer, principal financial officer and principal accounting officer, each with a $300,000 annual base salary, a target bonus equal to 50% of base salary, and a new hire option to purchase 150,000 Aurinia common shares. On March 20, 2026, prior officers including CEO Peter Greenleaf, COO Matthew Donley, CMO Gregory Keenan and CFO Joseph Miller ceased serving as officers, and Greenleaf resigned from the Board on March 21, 2026 but will consult for three months at $600 per hour to support the transition.
The Board created a new Lead Independent Director role and elected current independent director Craig Johnson to that position to help coordinate independent director activities and serve as liaison with the Chair and senior management.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan had 8,069 shares of Common Stock withheld on March 6, 2026 to cover tax obligations when restricted stock units vested. These shares were valued at $14.32 per share for this tax-withholding calculation. After this routine withholding, Keenan directly holds 154,449 common shares, showing he maintains a substantial equity position in the company.
Aurinia Pharmaceuticals Inc. director-associated entities reported significant open-market purchases of common shares. Limited partnerships associated with Kevin Tang bought a total of 900,000 common shares of Aurinia between February 27 and March 3, 2026, in a series of indirect transactions labeled “By LP.”
The purchases were executed at weighted-average prices around the mid-teens per share, with footnotes stating that the trades occurred in multiple transactions within ranges such as $13.51–$14.23 and several other bands in the low-to-mid $14 area. Following these buys, entities associated with Tang were reported as beneficially owning over 12 million Aurinia common shares.
Tang Capital Management and affiliates have updated their ownership disclosure for Aurinia Pharmaceuticals Inc. common shares. As of this amendment, the reporting group beneficially owns 12,229,500 common shares, representing 9.2% of Aurinia’s outstanding stock based on 132,970,979 shares as of February 25, 2026.
Since March 4, 2025, the reporting persons spent approximately $26.3 million to purchase 2,200,000 Aurinia common shares in open‑market transactions in the ordinary course of business. Voting and dispositive power over these shares is shared among Tang Capital Management, Tang Capital Partners entities and Kevin Tang under a joint filing arrangement.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Financial Officer Joseph M. Miller. On February 27, 2026, he received a grant of 95,700 employee stock options with an exercise price of $0.0000 per share and an award of 57,229 shares of common stock at no cost. The options vest one-third after twelve months from the grant date, with the remaining two-thirds vesting in twenty-four equal monthly installments.
Each performance right associated with these awards represents a contingent right to receive one common share, vesting in four tranches as the share price reaches progressively higher targets, each with a one-year retention period. On March 2, 2026, 37,511 common shares at $14.21 per share were withheld as a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving Miller with 576,421 directly held common shares.
Aurinia Pharmaceuticals Inc. Chief Operating Officer Matthew Maxwell Donley reported equity compensation and related tax withholding transactions. On February 27, 2026, he received a grant of 97,256 employee stock options at an exercise price of $0.00 per share and a grant of 58,160 shares of common stock at no cost, both held directly.
Following the stock award, his directly held common stock position increased to 721,060 shares. On March 2, 2026, 40,761 common shares valued at $14.21 per share were disposed of through a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving 680,299 common shares held directly.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Executive Officer Peter Greenleaf. He received a grant of 328,424 employee stock options at an exercise price of $0.0000 per share, with one-third vesting twelve months from the grant date and the remainder vesting in twenty-four equal monthly installments thereafter.
On the same grant date, he also acquired 196,403 shares of common stock through an award. Separately, 100,890 common shares were disposed of to cover tax withholding obligations upon the vesting of restricted stock units. Following these transactions, he directly owned 1,840,379 common shares.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan received new equity awards on February 27, 2026. He was granted stock options for 67,870 shares at an exercise price of $0, increasing his option holdings to 67,870 shares.
He also acquired 40,586 shares of common stock as a grant or award at a stated price of $0, bringing his directly held common shares to 162,518. Footnotes explain that related performance rights vest in tranches based on share price targets and time-based vesting schedules.
Aurinia Pharmaceuticals Inc. executive vice president and general counsel Stephen P. Robertson reported multiple equity transactions. On February 27, 2026, he received a grant of 98,813 employee stock options with a $0 exercise price and a separate award of 59,090 common shares, both held directly.
On March 2, 2026, 36,525 common shares were disposed of to satisfy tax withholding obligations upon vesting of restricted stock units, at a price of $14.21 per share. After these transactions, he directly owned 505,861 common shares.